Lyamtech, a regional SME, specializing in a niche diagnostic and manufacturing business in light medical devices, caters to patients with reduced mobility on medical prescription. This operation enables the Lyamtech Group to continue its external growth policy with the aim of consolidating its position as the French leader in podo-orthotics.
With the entry of the ARKEA CAPITAL GESTION fund, the Lyamtech Group is entering a new stage in its development. Independently of the financial support provided by this operation, it reinforces the quality of its industrial project and its vision of the market.
As Marc Brière, Managing Director of Arkéa Capital Investissement explains: “The strengthening of Lyamtech’s equity capital should enable it to become the benchmark player in the field of podo-orthotics and to actively participate in the restructuring of the market. This operation fully reflects our desire to support growing companies in our regions and to contribute to the economic vitality of the region. »
Arnaud Cardinet, CEO of I-Deal Development, is also very satisfied with this operation: “I-Deal Development has been able to integrate all the sensitivities of my capital-intensive environment with constancy and relevance. This sixth operation (LBO, acquisitions, share buybacks, capital increase…), over a period of three years, offers a new dynamic to my Group, already a leader, and will enable me to make it the national reference in my sector”.